Group 1 - BillionToOne officially listed on NASDAQ with an opening stock price surge of 81.57%, reaching a market capitalization of nearly $4.8 billion [1] - The IPO price was set at $60, with the stock opening at $100 and peaking at $123.45 during trading, indicating strong investor interest [1] - The company raised $273 million by issuing 4.55 million shares, with the offering size increased by 20% within regulatory limits [1] Group 2 - BillionToOne specializes in non-invasive prenatal testing (NIPT) and tumor blood testing based on single-molecule sequencing technology [2] - The company reported an 82% year-over-year revenue growth and a doubling of gross profit for the first half of the year, showcasing strong commercialization capabilities [2] - The successful IPO of BillionToOne is seen as a significant signal of recovery in the IPO market, particularly for high-growth medical technology companies [2]

Core Insights - BillionToOne, Inc. successfully completed an upsized initial public offering (IPO) of 4.6 million shares at $60 per share, raising approximately $273.1 million in gross proceeds [1] - The shares began trading on the Nasdaq Global Select Market on November 6, 2025, with the offering expected to close on November 7, 2025 [1] Company Representation - Gunderson Dettmer has represented BillionToOne through various financing rounds, including Series A and late-stage equity and debt private rounds, providing strategic counsel from early funding to public market entry [2] Underwriters - J.P. Morgan, Piper Sandler, Jefferies, and William Blair are acting as joint book-running managers for the IPO, with Stifel, Wells Fargo Securities, and BTIG also participating as book-running managers [3] Legal Team - The Gunderson deal team included several partners and associates specializing in corporate law and public offerings, showcasing the firm's expertise in navigating complex capital markets [4]

Group 1 - The government shutdown has impacted the IPO market, but some companies have still managed to go public [1][2] - Three companies went public on a recent Thursday, with BillionToOne being one of them [2] - BillionToOne, a molecular diagnostics company, priced its IPO at $60 per share and saw its stock nearly double to around $120 on its first trading day, resulting in a valuation of approximately $6.4 billion [3] Group 2 - BillionToOne raised $273 million from its stock sale, trading on the Nasdaq under the ticker symbol BLLN [3]

BillionToOne has become a newly minted public company, raising $273.1m in an upsized initial public offering (IPO), despite the longest government shutdown in US history hampering those wishing to join the stock exchange. The US-based company sold around 4.5 million shares of its common stock at $60 each. The molecular test developer initially offered around 3.8 million shares that were expected to fall between $49 and $55 each. BillionToOne’s IPO has given it a market valuation at around $2.6bn. The mol ...

Core Insights - Shares of BillionToOne increased by 66.67% during their Nasdaq debut, indicating strong market interest and investor confidence in the company [1] - The market valuation of BillionToOne reached $4.4 billion following the initial public offering, reflecting the company's growth potential in the molecular diagnostics sector [1] Company Summary - BillionToOne is a molecular diagnostics firm that has successfully launched its shares on Nasdaq, marking a significant milestone for the company [1] - The substantial rise in share price on debut suggests a positive reception from investors, which may enhance the company's visibility and credibility in the industry [1] Industry Context - The molecular diagnostics industry is experiencing increased investor interest, as evidenced by BillionToOne's successful IPO and significant valuation [1] - The performance of BillionToOne may indicate broader trends in the diagnostics market, where innovative companies are attracting capital and attention [1]

Core Insights - Molecular diagnostics firm BillionToOne successfully raised $273.1 million in its U.S. initial public offering (IPO) [1] - The company priced its shares above the marketed range, indicating strong investor demand [1] Company Summary - BillionToOne specializes in molecular diagnostics, a sector focused on the analysis of biological markers in the genome and proteome [1] - The successful IPO reflects the growing interest and investment in the molecular diagnostics industry [1] Financial Highlights - The total amount raised in the IPO was $273.1 million, showcasing significant capital influx for the company [1] - Pricing of shares above the marketed range suggests a positive market reception and confidence in the company's future prospects [1]

Core Insights - BillionToOne Inc. successfully raised $273.1 million in an upsized US initial public offering despite the ongoing US government shutdown, which has complicated the listing process [1][4]. Company Overview - The company, based in Menlo Park, California, sold 4.55 million shares at $60 each, exceeding the initially marketed range of $49 to $55 for 3.85 million shares [2]. - Following the IPO, BillionToOne's market value is estimated to be over $2.6 billion, with co-founders holding 64% of the voting power [3]. Financial Performance - For the six months ending June 30, BillionToOne reported a net loss of $4.2 million on revenue of $125.5 million, an improvement from a net loss of $15.2 million on revenue of $69.1 million during the same period the previous year [5]. Product Offerings - The company specializes in precision diagnostics, with its flagship product, Unity Complete, being a non-invasive prenatal screening test. Additionally, it offers NorthStar liquid biopsy tests that can detect tumor mutations [5]. Investor Information - Major investors include Hummingbird Ventures, which is expected to hold 19.9% of Class A shares post-IPO, Neotribe Ventures with 11%, and Libertus Capital with 9% [6]. - The IPO is being led by JPMorgan Chase & Co., Piper Sandler Cos., Jefferies Financial Group Inc., and William Blair & Co. The shares are expected to begin trading on the Nasdaq Global Select Market under the symbol BLLN [6].

Core Points - BillionToOne, Inc. has announced the pricing of its upsized initial public offering (IPO) of 4,551,100 shares at a price of $60.00 per share, with gross proceeds expected to be approximately $273.1 million [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025, and is expected to close on November 7, 2025, subject to customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 682,665 shares at the initial public offering price [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [5] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [5] Underwriters - The joint book-running managers for the offering include J.P. Morgan, Piper Sandler, Jefferies, and William Blair, with Stifel, Wells Fargo Securities, and BTIG also acting as book-running managers [2]

Core Insights - Eight new stocks were listed last week, including one direct listing company, raising significant capital across various sectors [1][2][3]. Group 1: Recent IPOs - MapLight Therapeutics (MPLT) raised $251 million by issuing 14.75 million shares at $17 each [1]. - Navan (NAVN) raised $923 million by issuing 36.92 million shares at $25 each [1]. - Boyd Group Services (BGSI) raised $780 million by issuing 5.5 million shares at $141 each [2]. - Nomadar (NOMA) entered Nasdaq through a direct listing [3]. Group 2: Upcoming IPOs - BETA Technologies, Inc. plans to list on NYSE with a target date of November 4, 2025, aiming to raise approximately $825 million by issuing 25 million shares at $27 to $33 each. The company reported revenue of $15.57 million in the first half of 2025, up from $7.59 million in the same period last year, with a net loss of $159 million [4][6]. - Exzeo Group, Inc. plans to list on NYSE on November 5, 2025, aiming to raise about $176 million by issuing 8 million shares at $20 to $22 each. The company reported revenue of $109 million in the first half of 2025, up from $60.31 million year-over-year, with a net profit of $39.61 million [6][8]. - Evommune, Inc. plans to list on NYSE on November 6, 2025, aiming to raise approximately $159 million by issuing 9.38 million shares at $15 to $17 each. The company reported revenue of $3 million in the first half of 2025, down from $7 million year-over-year, with a net loss of $28.12 million [10]. - Grupo Aeroméxico, S.A.B. de C.V. plans to list on NYSE on November 6, 2025, aiming to raise about $235 million by issuing 11.73 million shares at $18 to $20 each. The company reported revenue of $2.498 billion in the first half of 2025, down from $2.695 billion year-over-year, with a net profit of $89.97 million [12]. - BillionToOne, Inc. plans to list on NASDAQ on November 6, 2025, aiming to raise approximately $212 million by issuing 3.85 million shares at $49 to $55 each. The company reported revenue of $126 million in the first half of 2025, up from $69.09 million year-over-year, with a net loss of $4.23 million [14]. - Off The Hook YS Inc. plans to list on NYSE MKT on November 7, 2025, aiming to raise about $30 million by issuing 5 million shares at $4 to $6 each. The company reported revenue of $58.59 million in the first half of 2025, up from $51.85 million year-over-year, with a net profit of $840,000 [16].

Core Viewpoint - BillionToOne, Inc. has launched a roadshow for its proposed initial public offering (IPO) of 3,846,000 shares of Class A common stock, with an expected price range of $49.00 to $55.00 per share [1]. Company Overview - BillionToOne is a molecular diagnostics company based in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4]. - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4]. IPO Details - The proposed IPO includes a 30-day option for underwriters to purchase an additional 576,900 shares at the initial offering price, excluding underwriting discounts and commissions [1]. - The company has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "BLLN" [1]. - J.P. Morgan, Piper Sandler, Jefferies, and William Blair are acting as joint book-running managers for the offering, with Stifel, Wells Fargo Securities, and BTIG also participating as book-running managers [1].